Fennec Pharmaceuticals Insider Trading
TSX FRX
4
All Trades
1
Significant
1
Notable
0
Clusters
3
Repeat
Healthcare
Sector
Biotechnology
Industry
$548.5M
Market Cap
8.10 – 17.01
52 Week Range
790
Avg. Volume
| Company | Insider | Title | Tr. Date | Fi. Date | Shares | Price | Value | Balance | Increase | Signal |
|---|---|---|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals | Andrade, Robert | CFO | 19-Feb-26 | 24-Feb-26 | 260,024 | MN RP | ||||
| Fennec Pharmaceuticals | Andrade, Robert | CFO | 14-Jan-26 | 16-Jan-26 | 256,016 | MN RP | ||||
| Fennec Pharmaceuticals | Andrade, Robert | CFO | 07-Jan-26 | 08-Jan-26 | 246,016 | NT RP | ||||
| Fennec Pharmaceuticals | Hackman, Jeffrey | CEO | 19-May-25 | 19-May-25 | 15,000 | SI |
Fennec Pharmaceuticals (FRX): Insider trading △ Insider buy
Volume (thousands)
Related Companies to Explore
Company Info
Fennec Pharmaceuticals is a commercial stage biopharmaceutical company operating in the United States, working in the biotechnology sector within the healthcare industry. The company’s primary product candidate is PEDMARK, a formulation of sodium thiosulfate designed to prevent cisplatin-induced hearing loss in pediatric patients. Fennec sells its products through regional pediatric oncology specialists and medical science liaisons.
The company has established two notable collaborations. The first is with Tampa General Hospital Foundation, Inc., focused on evaluating the clinical usefulness of sodium thiosulfate injection in reducing the risk of hearing loss in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment. The second collaboration is with Norgine Pharma UK Limited. Fennec Pharmaceuticals was formerly known as Adherex Technologies Inc., a name it changed in September 2014. The company is based in Research Triangle Park, North Carolina, and was incorporated in 1996.
Don’t miss today’s trades
Full access to real-time insider buying data — $8.25/mo, billed annually. Cancel anytime.